Tralokinumab-ldrm 300 mg/2 mL Single-Dose Autoinjector Available in US

The Adbry® (tralokinumab-ldrm) 300 mg/2 mL single-dose autoinjector is now available in the United States for patients 12 and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable, LEO Pharma Inc. announced.

Prior to the introduction of the autoinjector device, Adbry was available only in a 150mg/1mL pre-filled syringe. With the new 300 mg/2 mL autoinjector device, adult patients now have another convenient option and half the number of required injections compared to the 150 mg/1 mL pre-filled syringe, LEO Pharma Inc. said in a press release.

“I understand from discussions with my patients that living with AD already brings a wide range of difficulties and debilitating factors that need to be managed on a daily basis, so it is integral that any treatment solution is more convenient to manage for those living with the condition, and does not add even more of a burden,” Jonathan Silverberg, MD, PhD, Professor of Dermatology at George Washington University, said in the press release. “This new administration option reduces the number of injections required overall and provides adults living with AD with an additional option in how they manage their condition.” 

For patients who prefer the pre-filled syringe, this option will continue to be available in the US for both adults and pediatric patients (age 12-17). 

“We are proud to expand the administration options for Adbry and the choices available for those adults who are living with AD,” said Brian Hilberdink, EVP and President, Region North America, LEO Pharma.